Three-Pronged attack on aggressive lung cancer in seniors
NCT ID NCT05685550
Summary
This study is testing a new combination of three drugs—etoposide, anlotinib, and envafolimab—as a first treatment for older adults (65+) with extensive small cell lung cancer. The main goal is to see if this combo is safe and can help control the cancer and delay its progression. Researchers will follow 30 patients to measure how long they live without the cancer getting worse and monitor their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSION-FREE SURVIVAL, PFS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Cancer Hospital Airport Hospital
Tianjin, 300450, China
Conditions
Explore the condition pages connected to this study.